KR20230167291A - Antimicrobial peptide delivery system and manufacturing method based on gold nanoparticles-aptamer conjugate - Google Patents
Antimicrobial peptide delivery system and manufacturing method based on gold nanoparticles-aptamer conjugate Download PDFInfo
- Publication number
- KR20230167291A KR20230167291A KR1020220184356A KR20220184356A KR20230167291A KR 20230167291 A KR20230167291 A KR 20230167291A KR 1020220184356 A KR1020220184356 A KR 1020220184356A KR 20220184356 A KR20220184356 A KR 20220184356A KR 20230167291 A KR20230167291 A KR 20230167291A
- Authority
- KR
- South Korea
- Prior art keywords
- antibacterial peptide
- aptamer
- antibacterial
- wlbu2
- gold nanoparticles
- Prior art date
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 55
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 229910052737 gold Inorganic materials 0.000 title claims abstract description 47
- 239000010931 gold Substances 0.000 title claims abstract description 47
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 108700042778 Antimicrobial Peptides Proteins 0.000 title description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 title description 3
- 108091023037 Aptamer Proteins 0.000 claims abstract description 45
- 239000002105 nanoparticle Substances 0.000 claims abstract description 45
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 5
- 241000194031 Enterococcus faecium Species 0.000 claims description 3
- 241000605986 Fusobacterium nucleatum Species 0.000 claims description 3
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 2
- 241001136175 Burkholderia pseudomallei Species 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 241000588697 Enterobacter cloacae Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000589602 Francisella tularensis Species 0.000 claims description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 2
- 241000194026 Streptococcus gordonii Species 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 239000003674 animal food additive Substances 0.000 claims description 2
- 229940118764 francisella tularensis Drugs 0.000 claims description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 2
- 239000000273 veterinary drug Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 14
- 239000003242 anti bacterial agent Substances 0.000 abstract description 8
- 230000001939 inductive effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 241000192125 Firmicutes Species 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 4
- 239000000562 conjugate Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000122971 Stenotrophomonas Species 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 125000003345 AMP group Chemical group 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000604933 Bdellovibrio Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241001240958 Pseudomonas aeruginosa PAO1 Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010054557 WLBU2 peptide Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Ceramic Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명은 항균 펩타이드를 세포 내로 효율적으로 전달하고 발현을 유도할 수 있는 전달체로서, 금 나노 입자 및 항균 펩타이드에 특이적으로 결합하는 앱타머를 포함하는 항균 펩타이드 전달체, 이의 제조 방법 및 이를 포함하는 항균용 조성물에 대한 것이다. The present invention is a carrier capable of efficiently delivering antibacterial peptides into cells and inducing expression, an antibacterial peptide carrier comprising gold nanoparticles and an aptamer that specifically binds to an antibacterial peptide, a method for manufacturing the same, and an antibacterial agent comprising the same. This is about the composition.
Description
본 발명은 본 발명은 금 나노 입자-앱타머 결합체를 기반으로 하는 항균 펩타이드 전달체 및 이의 제조 방법에 관한 것으로서, 보다 구체적으로는 금 나노 입자에 항균 펩타이드에 특이적인 앱타머를 제작 및 결합하여 세포 내로 항균 펩타이드의 전달능이 향상된 항균 펩타이드 전달체 및 이의 제조 방법에 관한 것이다. The present invention relates to an antibacterial peptide delivery system based on a gold nanoparticle-aptamer conjugate and a method for producing the same. More specifically, the present invention relates to an antibacterial peptide-specific aptamer produced and bound to gold nanoparticles to be delivered into cells. It relates to an antibacterial peptide delivery system with improved delivery capacity of antibacterial peptides and a method for manufacturing the same.
기존의 항균제에 대한 박테리아 내성은 해마다 증가하고 있으며 전 세계적인 보건 분야의 주요한 문제 중 하나이다. 현재 전 세계적으로 이루어지는 감염성 질환에 대한 연구는 대부분 병원균의 대사나 생합성 경로를 선택적으로 억제 및 제어하는 항생물질의 개발과 약독화 병원균 배양에 의한 백신개발에 그 초점이 맞추어져 있는데 기존의 항생물질의 경우 숙주의 대사 및 생합성 경로를 조절하는 효소도 동시에 억제하여 부작용과 독성을 나타내는 경우가 많으며 그 내성 문제로 사용이 제한되고 있다. 그러므로 감염성 질환을 초기에 효과적으로 제어 가능한 새로운 패러다임의 개발이 시급하며 그 실례로 항균 펩타이드(antimicrobial peptides, AMP)에 주목을 하고 있다. Bacterial resistance to existing antibacterial agents is increasing every year and is one of the major problems in global health. Currently, most research on infectious diseases around the world focuses on the development of antibiotics that selectively inhibit and control the metabolic or biosynthetic pathways of pathogens and the development of vaccines by culturing attenuated pathogens. In this case, it simultaneously inhibits enzymes that regulate the host's metabolic and biosynthetic pathways, often causing side effects and toxicity, and its use is limited due to resistance issues. Therefore, the development of a new paradigm that can effectively control infectious diseases at an early stage is urgent, and attention is being paid to antimicrobial peptides (AMP) as an example.
대부분의 AMP는 정전기력을 통해 박테리아 막을 선택적으로 표적으로 하는 양친매성 구조를 가진 양이온성 펩타이드이다. 이 중 WLBU2는 상피 세포 독성을 최소화하면서 항균 특성을 최대화하기 위해 이상적인 양친매성 나선 구조를 갖도록 전구체 펩타이드의 아미노산 치환에 의해 합리적으로 설계되었다. 그러나 이러한 항균 펩타이드의 전달을 실용화를 위하여 정상세포에도 해를 입힐 수 있는 독성을 유발할 수 있고, 전달 약물을 오랜 시간 보관하지 못하는 단점과 전달 정확도가 낮은 문제점을 가지고 있다.Most AMPs are cationic peptides with an amphipathic structure that selectively target bacterial membranes through electrostatic forces. Among these, WLBU2 was rationally designed by amino acid substitution of the precursor peptide to have an ideal amphipathic helical structure to maximize antibacterial properties while minimizing epithelial cell toxicity. However, in order to commercialize the delivery of these antibacterial peptides, there are problems in that it can cause toxicity that can harm normal cells, the delivered drug cannot be stored for a long time, and the delivery accuracy is low.
본 발명자들은 이전 연구에서 항체 전달을 위한 나노 입자 복합체를 제조한 바 있으며, 금 나노입자-앱타머의 결합체를 기반으로 하는 항체 전달체의 경우, 세포 내 항체 전달능이 향상되고 안정성이 뛰어난 효과를 확인하였다. 이에 상기 항균 펩타이드의 경우에도 약물 전달능이 우수하면서도 항균 펩타이드가 가질 수 있는 독성이나 보관 안정성과 같은 문제점을 해결할 수 있는 우수한 나노 입자 기반의 전달체 개발이 요구되고 있는 실정이다. In previous research, the present inventors have manufactured a nanoparticle complex for antibody delivery, and in the case of an antibody delivery vehicle based on a gold nanoparticle-aptamer conjugate, it was confirmed that the intracellular antibody delivery ability was improved and the effect of excellent stability was confirmed. . Accordingly, in the case of the antibacterial peptide, there is a need to develop an excellent nanoparticle-based delivery system that has excellent drug delivery ability and can solve problems such as toxicity and storage stability that antibacterial peptides may have.
이에 본 발명자들은 독성이 없으면서, 항균 펩타이드 (WLBU2)를 세포 내로 효율적으로 전달하고 발현을 유도할 수 있는 유전자 운반 기술을 개발하고자 예의 연구 노력하였다. 그 결과, SELEX 기법을 활용하여 상기 항균 펩타이드와 결합력이 월등히 높아진 앱타머를 개발하고, 이를 생체 내에 효과적으로 전달하기 위하여 나노 입자(AuNP)와 공유 결합으로 도입하여 복합체를 만든 후, 항균 펩타이드(WLBU2)와 결합하여, 항균 펩타이드를 안정적으로 체내 전달할 수 있는 본 발명을 완성하게 되었다.Accordingly, the present inventors made extensive research efforts to develop a gene delivery technology that can efficiently deliver an antibacterial peptide (WLBU2) into cells and induce its expression without toxicity. As a result, using the SELEX technique, we developed an aptamer with significantly higher binding strength to the antibacterial peptide, and in order to effectively deliver it in vivo, we introduced it by covalent bonding with nanoparticles (AuNP) to create a complex, and then added the antibacterial peptide (WLBU2). In combination with this, the present invention, which can stably deliver antibacterial peptides into the body, was completed.
따라서 본 발명의 목적은 나노 입자에 결합 가능한 항균 펩타이드의 타겟 앱타머 개발 및 금 나노 입자 물질을 포함하는 항균 펩타이드 전달체를 제공하는 것이다. Therefore, the purpose of the present invention is to develop a target aptamer for an antibacterial peptide that can bind to nanoparticles and to provide an antibacterial peptide carrier containing a gold nanoparticle material.
본 발명의 다른 목적은 항균 펩타이드에 특이적인 앱타머를 제작하는 단계, 상기 앱타머를 금 나노 입자에 결합시키는 단계를 포함하는 항균 펩타이드 전달체의 제조 방법을 제공하는 것이다. Another object of the present invention is to provide a method for producing an antibacterial peptide delivery system comprising the steps of preparing an aptamer specific for an antibacterial peptide and binding the aptamer to a gold nanoparticle.
본 발명의 다른 목적은, 상기 항균 단백질 전달체를 포함하는 항균제 조성물을 제공하는 것이다.Another object of the present invention is to provide an antibacterial agent composition containing the antibacterial protein carrier.
상기와 같은 목적을 달성하기 위하여, 본 발명은 SELEX 기법을 통하여 제작된 나노 입자에 결합 가능한 항균 펩타이드인 WLBU2의 타겟 앱타머 및 금 나노 입자 물질을 포함하는 항균 펩타이드 전달체를 제공한다. In order to achieve the above object, the present invention provides an antibacterial peptide carrier containing a target aptamer of WLBU2, an antibacterial peptide capable of binding to nanoparticles produced through the SELEX technique, and a gold nanoparticle material.
본 발명의 다른 목적을 달성하기 위하여 본 발명은 항균 펩타이드인 WLBU2 에 특이적인 앱타머를 제작하는 단계, 상기 앱타머를 금 나노 입자에 결합시키는 단계를 포함하는 항균 펩타이드 전달체의 제조 방법을 제공한다. In order to achieve another object of the present invention, the present invention provides a method for producing an antibacterial peptide delivery system comprising the steps of preparing an aptamer specific for the antibacterial peptide WLBU2 and binding the aptamer to gold nanoparticles.
본 발명의 다른 목적을 달성하기 위하여 본 발명은, 상기 항균 단백질 전달체를 포함하는 항균제 조성물을 제공한다. In order to achieve another object of the present invention, the present invention provides an antibacterial agent composition containing the antibacterial protein carrier.
이하, 본 발명을 상세하게 설명한다. Hereinafter, the present invention will be described in detail.
본 발명의 일 양태로서, 본 발명은 나노 입자에 결합 가능한 항균 펩타이드의 타겟 앱타머 및 금 나노 입자 물질을 포함하는 항균 펩타이드 전달체에 대한 것이다. In one aspect of the present invention, the present invention relates to an antibacterial peptide carrier comprising a target aptamer of an antibacterial peptide capable of binding to nanoparticles and a gold nanoparticle material.
본 발명에서 상기 '나노 입자(NP, nanoparticle)'는 나노 단위의 직경을 가지는 금속 입자로서, 바람직하게는 '금 나노 입자'를 의미하며, 본 발명의 금 나노 입자는 표적이 되는 세포로 침투하는 것을 용이하게 하여 세포 내에 펩타이드를 전달하는 역할을 한다. In the present invention, the 'nanoparticle (NP)' refers to a metal particle having a nanoscale diameter, preferably 'gold nanoparticle', and the gold nanoparticle of the present invention penetrates into the target cell. It serves to facilitate the delivery of peptides into cells.
상기 금 나노 입자는 안정한 입자의 형태로 제조가 쉬울 뿐만 아니라 0.8 nm에서 200 nm까지 다양하게 사용 목적에 맞추어 크기를 변화시킬 수 있다. 또한, 금은 다양한 종류의 분자들, 예컨대 펩타이드, 단백질, 핵산 등과 함께 결합하여 구조를 변형시킬 수 있고, 다양한 파장에서 빛에 반사하는 바, 이를 이용해 세포 내에서의 위치를 쉽게 확인할 수 있다. 더욱이, 금 나노 입자는 망간, 알루미늄, 카드늄, 납, 수은, 코발트, 니켈, 베릴륨 등의 중금속과 달리 인체에 무해하여 높은 생체친화성을 가지며, 매우 적은 세포 독성을 가지는 장점이 있다. The gold nanoparticles are not only easy to manufacture in the form of stable particles, but can also vary in size from 0.8 nm to 200 nm to suit the purpose of use. In addition, gold can modify the structure by combining with various types of molecules, such as peptides, proteins, and nucleic acids, and reflects light at various wavelengths, making it easy to confirm its location within the cell. Moreover, unlike heavy metals such as manganese, aluminum, cadmium, lead, mercury, cobalt, nickel, and beryllium, gold nanoparticles are harmless to the human body, have high biocompatibility, and have the advantage of very low cytotoxicity.
금 나노 입자는 직경이 100 nm 이상으로 커질 경우 나노 입자로서의 특성이 소멸될 뿐 아니라, 나노 물질의 특성이 없는 금 표면과 티올기 등의 작용기와의 결합이 약해지고, 직경이 10-20 nm 이외의 금 나노 입자는 세포독성을 유발하기 때문에, 본 발명의 금 나노입자는 직경은 10~20 nm의 크기를 가지는 것이 바람직하다.When the diameter of gold nanoparticles increases beyond 100 nm, not only do their characteristics as nanoparticles disappear, but the bond between the gold surface, which does not have the characteristics of nanomaterials, and functional groups such as thiol groups is weakened, and the gold nanoparticles have a diameter other than 10-20 nm. Since gold nanoparticles cause cytotoxicity, the gold nanoparticles of the present invention preferably have a diameter of 10 to 20 nm.
본 발명에서 상기 "앱타머(aptamer)"는 짧은 길이의 올리고머(oligomer)로서, 안정한 구조를 형성하여 표적 물질에 높은 결합력과 특이성을 가지고 결합하는 특징을 가지는 단일가닥 핵산으로, 분자 내 수소결합에 의해 특징적인 3차원의 구조를 형성한다. 이러한 공간적 구조를 통하여 표적에 특이적인 결합을 할 수 있다. 앱타머는 SELEX(Systematic Evolution of Ligands of Exponential enrichment)를 이용하여 개발할 수 있고, 표적에 대한 높은 친화성과 특이성을 가지므로, 단백질, 당, 핵산, 금속이온 등 다양한 타겟에 결합할 수 있는 앱타머의 개발이 가능하다. In the present invention, the "aptamer" is a short-length oligomer, a single-stranded nucleic acid that forms a stable structure and has the characteristic of binding to the target substance with high binding force and specificity, and is characterized by intramolecular hydrogen bonding. It forms a characteristic three-dimensional structure. Through this spatial structure, specific binding to the target is possible. Aptamers can be developed using SELEX (Systematic Evolution of Ligands of Exponential enrichment) and have high affinity and specificity for the target, so the development of aptamers can bind to various targets such as proteins, sugars, nucleic acids, and metal ions. This is possible.
본 발명의 항균 단백질인 WLBU2는 서열 번호 2 내지 서열번호 5의 아미노산 서열 또는, 상기 서열 번호 1 내지 4의의 아미노산 서열과 70% 이상, 80% 이상, 90% 이상, 95% 이상, 97% 이상 또는 99% 이상 서열 동일성을 가질 수 있다. 알려진 WLBU2 단백질 구조는 주로 Arg(13개 잔기) 및 Val(8개 잔기)로 구성되어 있고, 소수성 면에 3개 Trp 잔기가 7개 이상의 아미노산으로 서로 분리되어 있는 구조를 포함하여 양 친매성인 특징을 가진다. WLBU2, an antibacterial protein of the present invention, has the amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 5, or the amino acid sequence of SEQ ID NO: 1 to 4 and 70% or more, 80% or more, 90% or more, 95% or more, 97% or more It may have more than 99% sequence identity. The known WLBU2 protein structure consists mainly of Arg (13 residues) and Val (8 residues), and has amphipathic features, including a structure with three Trp residues on the hydrophobic side separated from each other by at least seven amino acids. have
본 발명의 상기 WLBU2는 그람 음성균, 그람 양성균, 항생제 내성 그람 음성균 및 항생제 내성 그람 양성균에 대해 항균 활성을 가질 수 있다. The WLBU2 of the present invention may have antibacterial activity against Gram-negative bacteria, Gram-positive bacteria, antibiotic-resistant Gram-negative bacteria, and antibiotic-resistant Gram-positive bacteria.
상기 '그람 음성균'은 엔도톡신(endotoxin)을 보유한 모든 종류의 그람 음성균이 포함되며, 예를 들어, 에스케리아(Escherichia) 속, 슈도모나스(Pseudomonas) 속, 아시네토박터(Acinetobacter) 속, 살모넬라(Salmonella) 속, 크렙시엘라(Klebsiella) 속, 나이세리아(Neisseria) 속, 엔테로박터(Enterobacter) 속, 시겔라(Shigella) 속, 모락셀라(Moraxella) 속, 헬리코박터(Helicobacter) 속, 스테노트로포모나스(Stenotrophomonas) 속, 브델로비브리오(Bdellovibrio) 속, 레지오넬라(Legionella) 속 균주 등이 포함되며, 이에 제한되지 않는다. The 'gram-negative bacteria' includes all types of gram-negative bacteria possessing endotoxin, for example, Escherichia genus, Pseudomonas genus, Acinetobacter genus, Salmonella ) genus, Klebsiella genus, Neisseria genus, Enterobacter genus, Shigella genus, Moraxella genus, Helicobacter genus, Stenotrophomonas Includes, but is not limited to, strains of the genus Stenotrophomonas, genus Bdellovibrio, and genus Legionella.
상기 '그람 양성균'은 스타필로코커스(Staphylococcus) 속, 엔테로코커스(Enterococcus) 속, 스트렙토코커스(Streptococcus) 속, 클로스트리디움(Clostridium) 속 균주 등이 포함될 수 있으나, 이에 제한되는 것은 아니다. The 'Gram-positive bacteria' may include, but are not limited to, strains of the Staphylococcus genus, Enterococcus genus, Streptococcus genus, and Clostridium genus.
또한 '항생제 내성 그람 양성균'은 예를 들어, 메티실린(Methicillin) 내성 그람 양성균, 카바페넴(Carbapenem) 내성 그람 양성균, 반코마이신(Vancomycin) 내성 그람 양성균, 마크롤라이드(Macrolide) 및 다제 내성 그람 양성균 등이 포함될 수 있고, '항생제 내성 그람 음성균'은 예를 들어, 스트렙토마이신(Streptomycin) 내성 그람 음성균, 콜리스틴(Colistin) 내성 그람 음성균, 카바페넴(Carbapenem) 내성 그람 음성균, 클로람페니콜(Chloramphenicol) 내성 그람 음성균, 테트라사이클린(Tetracyclines) 내성 그람 음성균, 세포탁심(Cefotaxime) 내성 그람 음성균, 광범위 베타락탐계 항생제 분해효소(ESBL;Extended Spectrum Beta Lactamase) 내성 그람 음성균, 티게사이클린(Tigecycline) 내성 그람 음성균 및 다제 내성 그람 음성균 등이 포함될 수 있으며, 이에 제한되는 것은 아니다. In addition, 'antibiotic-resistant Gram-positive bacteria' include, for example, methicillin-resistant Gram-positive bacteria, carbapenem-resistant Gram-positive bacteria, vancomycin-resistant Gram-positive bacteria, macrolide and multidrug-resistant Gram-positive bacteria, etc. may be included, and 'antibiotic-resistant Gram-negative bacteria' include, for example, Streptomycin-resistant Gram-negative bacteria, Colistin-resistant Gram-negative bacteria, Carbapenem-resistant Gram-negative bacteria, and Chloramphenicol-resistant Gram-negative bacteria. , Tetracycline-resistant Gram-negative bacteria, Cefotaxime-resistant Gram-negative bacteria, Extended Spectrum Beta Lactamase (ESBL)-resistant Gram-negative bacteria, Tigecycline-resistant Gram-negative bacteria, and multidrug-resistant Gram. Negative bacteria may be included, but are not limited thereto.
보다 구체적으로 본 발명의 항균 펩타이드가 항균 활성을 가지는 균은 슈도모나스 애루지노사(Pseudomonas aeruginosa), 아시네토박터 바우마니(Acinetobacter baumanii), 스트렙토코커스 고르도니(Streptococcus gordonii), 후소박테리움 뉴클레아툼(Fusobacterium nucleatum), 포르피로모나스 긴기발리스(Porphyromonas gingivalis), 프랜시셀라 툴라렌시스(Francisella tularensis), 여시니아 페스티스(Yersinia pestis), 버크홀데리아 슈도말레이 (Burkholderia pseudomallei), 스트렙토코커스 아우레우스(Staphylococcus aureus), MRSA, 엔테로코커스 패시움(Enterococcus faecium), 클렙시엘라 뉴모니아 (Klebsiella pneumoniae), 엔테로박터 클로아카(Enterobacter cloacae), 에스케리아 콜라이(Escherichia coli), 칸디다 종(Candida species)을 포함하는 군으로부터 선택된 하나 이상의 균일 수 있다.More specifically, the bacteria in which the antibacterial peptide of the present invention has antibacterial activity include Pseudomonas aeruginosa, Acinetobacter baumanii, Streptococcus gordonii, and Fusobacterium nucleatum. (Fusobacterium nucleatum), Porphyromonas gingivalis, Francisella tularensis, Yersinia pestis, Burkholderia pseudomallei, Streptococcus aureus (Staphylococcus aureus), MRSA, Enterococcus faecium, Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Candida species ) may be one or more uniforms selected from the group containing.
본 발명의 항균 단백질 전달체는 상기 항균 펩타이드를 표적 세포로 전달하기 위하여, 금 나노 입자 및 상기 항균 펩타이드에 결합하는 앱타머를 포함한다. 본 발명의 전달체에 포함되는 앱타머는 항균 펩타이드인 WLBU2에 특이적으로 결합하기 위한 핵산 서열을 포함하며, 상기 앱타머는 금나노 입자 표면에 결합되어, 항균 단백질과 금 나노 입자의 결합을 매개하는 역할을 한다. The antibacterial protein delivery vehicle of the present invention includes gold nanoparticles and an aptamer that binds to the antibacterial peptide in order to deliver the antibacterial peptide to target cells. The aptamer included in the delivery vehicle of the present invention contains a nucleic acid sequence for specifically binding to WLBU2, an antibacterial peptide, and the aptamer is bound to the surface of the gold nanoparticle and serves to mediate the binding between the antibacterial protein and the gold nanoparticle. do.
본 발명의 항균 단백질 전달체는 항균 펩타이드인 WLBU2에 특이적인 앱타머가 결합된 금 나노 입자를 포함하며, 이는 상기 항균 펩타이드의 세포 전달력을 향상시켜 WLBU2를 이용하는 항균제의 용도로서 활용할 수 있다. The antibacterial protein carrier of the present invention includes gold nanoparticles bound to an aptamer specific to the antibacterial peptide WLBU2, which improves the cell delivery ability of the antibacterial peptide and can be used as an antibacterial agent using WLBU2.
본 발명의 일 양태로서, 본 발명은 WLBU2에 특이적인 앱타머를 개발하는 단계; 상기 앱타머를 금 나노 입자와 결합하는 단계를 포함하는 항균 단백질 전달체의 제조 방법에 대한 것이다 In one aspect of the present invention, the present invention includes the steps of developing an aptamer specific for WLBU2; It relates to a method for producing an antibacterial protein carrier comprising combining the aptamer with gold nanoparticles.
본 발명의 다른 양태로서, 본 발명은 상기 항균 단백질 전달체를 포함하는 항균용 조성물에 대한 것이다. In another aspect of the present invention, the present invention relates to an antibacterial composition containing the antibacterial protein carrier.
본 명세서에서 사용된 용어, "항균용 조성물"은 세균이나 곰팡이와 같은 미생물의 생육을 저해하는 활성을 가진 조성물로서, 항균 효과가 요구되는 다양한 분야에 사용되는 모든 형태가 포함될 수 있으며, 예를 들어, 의약품, 화장품, 의약외품, 동물용 의약품, 식품 첨가제 또는 사료 첨가제 등의 형태일 수 있다. As used herein, the term “antibacterial composition” refers to a composition that has the activity of inhibiting the growth of microorganisms such as bacteria and mold, and may include all forms used in various fields requiring antibacterial effects, for example , it may be in the form of pharmaceuticals, cosmetics, quasi-drugs, veterinary drugs, food additives, or feed additives.
상기 항균용 조성물은 본 발명의 항균 단백질 전달체를 포함하며, 항 미생물 제제, 항 바이러스 제제 및 항 진균제로서 광범위하게 사용될 수 있다. 적용 범위는 식물, 동물 및 인간에게 널리 해롭게 작용하고 있는 바이러스, 항균용 조성물의 항균 대상은 그람 음성균, 그람 양성균, 항생제 내성 그람 음성균 및 항생제 내성 그람 양성균 등이 포함되며, 곰팡이, 효모 및 원생동물 등에 적용될 수 있다. 본 발명의 상기 항균제 조성물은 단독으로 사용될 수도 있고, 용도에 따라 다른 항생제와 함께 사용될 수도 있다. 또한, 약학적 용도 이외에 식품 첨가물, 화장품, 연고 또는 주사제 등의 용도로도 유용하게 사용될 수 있다.The antibacterial composition contains the antibacterial protein carrier of the present invention and can be widely used as an antimicrobial agent, antiviral agent, and antifungal agent. The scope of application includes viruses that are widely harmful to plants, animals, and humans. The antibacterial targets of the antibacterial composition include gram-negative bacteria, gram-positive bacteria, antibiotic-resistant gram-negative bacteria, and antibiotic-resistant gram-positive bacteria, as well as mold, yeast, and protozoa. It can be applied. The antibacterial composition of the present invention may be used alone or in combination with other antibiotics depending on the intended use. In addition, in addition to pharmaceutical uses, it can also be usefully used for purposes such as food additives, cosmetics, ointments, or injections.
본 발명은 항균 펩타이드인 WLBU2에 특이적인 앱타머가 결합된 금 나노 입자를 포함하는 항균 단백질 전달체로서, 이는 상기 항균 펩타이드의 세포 전달력을 향상시켜 표적에 대한 항균 효과를 극대화할 수 있는 효과를 가지므로, 항균 단백질을 이용하는 항균제의 용도로서 활용이 가능하다. The present invention is an antibacterial protein carrier containing gold nanoparticles bound to an aptamer specific to the antibacterial peptide WLBU2, which has the effect of maximizing the antibacterial effect on the target by improving the cell delivery ability of the antibacterial peptide. , it can be used as an antibacterial agent using antibacterial proteins.
도 1은 본 발명의 항균 펩타이드에 대한 타겟 앱타머를 개발하기 위한 과정을 설명한 개략도이다.
도 2는 본 발명의 항균 펩타이드에 특이적으로 결합하는 WLBU2-R 앱타머를 이용하여 항균 펩타이드 전달체인 AuNPWLBU2-R 를 제조하는 과정을 설명한 개략도를 도시한 것이다.
도 3 및 도 4는 금 나노 입자에 기능화된 앱타머(WLBU2-R)의 개수 및 이에 결합한 펩타이드 개수를 확인한 결과를 나타내는 도면이다.
도 5는 마우스에 세균 감염 후, AuNPWLBU2-R를 이용하여 항균 펩타이드를 전달한 경우, 전달 효율 및 항균 효과에 의한 생존율을 확인한 결과를 나타내는 도면이다.Figure 1 is a schematic diagram explaining the process for developing a target aptamer for the antibacterial peptide of the present invention.
Figure 2 shows a schematic diagram explaining the process of preparing AuNP WLBU2-R, an antibacterial peptide carrier, using the WLBU2 -R aptamer that specifically binds to the antibacterial peptide of the present invention.
Figures 3 and 4 are diagrams showing the results of confirming the number of aptamers (WLBU2-R) functionalized in gold nanoparticles and the number of peptides bound to them.
Figure 5 is a diagram showing the results of confirming the delivery efficiency and survival rate due to the antibacterial effect when antibacterial peptides were delivered using AuNP WLBU2-R after bacterial infection in mice.
도 1은 본 발명의 항균 펩타이드에 대한 타겟 앱타머를 개발하기 위한 과정을 설명한 개략도이다.Figure 1 is a schematic diagram explaining the process for developing a target aptamer for the antibacterial peptide of the present invention.
도 2는 본 발명의 항균 펩타이드에 특이적으로 결합하는 WLBU2-R 앱타머를 이용하여 항균 펩타이드 전달체인 AuNPWLBU2-R 를 제조하는 과정을 설명한 개략도를 도시한 것이다. Figure 2 shows a schematic diagram explaining the process of preparing AuNP WLBU2-R, an antibacterial peptide carrier, using the WLBU2 -R aptamer that specifically binds to the antibacterial peptide of the present invention.
도 3 및 도 4는 금 나노 입자에 기능화된 앱타머(WLBU2-R)의 개수 및 이에 결합한 펩타이드 개수를 확인한 결과를 나타내는 도면이다.Figures 3 and 4 are diagrams showing the results of confirming the number of aptamers (WLBU2-R) functionalized in gold nanoparticles and the number of peptides bound to them.
도 5는 마우스에 세균 감염 후, AuNPWLBU2-R를 이용하여 항균 펩타이드를 전달한 경우, 전달 효율 및 항균 효과에 의한 생존율을 확인한 결과를 나타내는 도면이다.Figure 5 is a diagram showing the results of confirming the delivery efficiency and survival rate due to the antibacterial effect when antibacterial peptides were delivered using AuNP WLBU2-R after bacterial infection in mice.
실시예 2. SELEX기법 이용한 WLBU2 앱타머 개발Example 2. Development of WLBU2 aptamer using SELEX technique
2-1. SELEX 기법을 통한 항균 펩타이드 타겟 앱타머 개발 2-1. Development of antibacterial peptide target aptamer using SELEX technique
SELEX (Systemic evolution of ligands by exponential enrichment) 방법을 활용하여 항균 펩타이드인 WLBU2에 특이적인 앱타머를 개발하였다. 총 11회의 SELEX 과정을 반복하였으며, WLBU2에 대한 결합력이 높은 최적의 앱타머들을 선별하였다. 앱타머의 선발 과정은 도 1에 도시된 과정에 따라 진행하였다. An aptamer specific to the antibacterial peptide WLBU2 was developed using the SELEX (Systemic evolution of ligands by exponential enrichment) method. The SELEX process was repeated a total of 11 times, and the optimal aptamers with high binding affinity to WLBU2 were selected. The aptamer selection process was carried out according to the process shown in Figure 1.
2-2 개발된 대표 4개의 타겟 앱타머 리스트2-2 List of four representative target aptamers developed
시퀀싱을 통하여 확인된 전체 서열 중 대조군에 비하여 WLBU2 결합하는 샘플 시료에서 2배이상의 Fold change를 보이는 대표 서열 4종류를 개발하였다. 그 서열 및 Fold change는 하기의 표 2에 리스트화 하였다. Among the total sequences identified through sequencing, four representative sequences were developed that showed more than twice the fold change in samples that bind to WLBU2 compared to the control group. The sequences and fold changes are listed in Table 2 below.
ChangeChange
-R-R
-R-3-R-3
실시예3. WLBU2-R이 기능화된 금 나노입자 (AuNPExample 3. WLBU2-R-functionalized gold nanoparticles (AuNPs) WLBU2-RWLBU2-R ) 제조) manufacturing
WLBU2 항균 펩타이드에 결합하는 WLBU2-R 앱타머를 이용하여 항균 펩타이드 전달체 AuNPWLBU2-R를 제조하였다. The antibacterial peptide carrier AuNP WLBU2-R was prepared using the WLBU2- R aptamer that binds to the WLBU2 antibacterial peptide.
3-1. WLBU2-R 전처리 3-1. WLBU2-R preprocessing
본 발명에 따른 항균 펩타이드 전달체를 제조하기 위해, 실시예 2에 기재된 방법에 따라 SELEX 기법을 이용하여 앱타머를 개발하였다. 개발된 앱타머 중, 3’말단이 티올기로 변형된 올리고 뉴클레오타이드로서 (SH) 5‘-AAAACGACGGCCAGTCCATCCATTGGCTGGGTTAATCTTTATTGGCTGGGATTAACTGGATGGTGCATGGTCATAGCTGTAAAAAAAAAA-3'(서열번호 1)의 염기서열로 이루어진 WLBU2-R를 선택하였다. 건조된 상기 WLBU2-R를 최종 농도가 100 μM이 되도록 물에 녹인 후, 150 μl의 올리고에 20μl의 3M 소듐아세테이트(pH 5.2)와 30μl의 1N DTT(dithiothreitol)를 넣고, 실온에서 60분간 반응시켰다. 원하지 않은 티올기 분자를 포함한 DTT를 제거하기 위해, 에틸아세테이트(Ethyl acetate) 200 μl를 넣고 섞은 후, 원심 분리하여 상층액을 제거하였으며, 이 과정을 3회 반복하였다. 그리고 나서 에탄올 침전법(EtOH precipitating method)을 이용하여 올리고WLBU2-R를 침전시켰다. To prepare the antibacterial peptide carrier according to the present invention, an aptamer was developed using the SELEX technique according to the method described in Example 2. Among the developed aptamers, WLBU2-R, which is an oligonucleotide whose 3' end is modified with a thiol group and has the base sequence of (SH) 5'-AAAACGACGGCCAGTCCATCCATTGGCTGGGTTAATCTTTATTGGCTGGGATTAACTGGATGGTGCATGGTCATAGCTGTAAAAAAAAAA-3' (SEQ ID NO: 1), was selected. After dissolving the dried WLBU2-R in water to a final concentration of 100 μM, 20 μl of 3M sodium acetate (pH 5.2) and 30 μl of 1N DTT (dithiothreitol) were added to 150 μl of oligo, and reacted at room temperature for 60 minutes. . To remove DTT containing unwanted thiol molecules, 200 μl of ethyl acetate was added and mixed, then centrifuged to remove the supernatant, and this process was repeated three times. Then, oligoWLBU2-R was precipitated using the ethanol precipitation method (EtOH precipitating method).
3-2 금 나노입자의 WLBU2-R 기능화 (AuNP3-2 WLBU2-R functionalization of gold nanoparticles (AuNP WLBU2-RWLBU2-R ) 제조 ) manufacturing
상기 3-1 과정을 통해 전처리되어 침전된 WLBU2-R를 물에 녹인 후, 금나노 입자에 첨가한 후 Salt aging 방법으로 결합시켰다. 구체적으로, 7 nM의 금 나노입자에 WLBU2-R 를 넣고 (AuNP : WLBU2-R = 1:300) 충분 히 섞은 후, 농도가 0.1M 이 되도록 NaCl을 첨가하여 4시간 혼합하였다. 4시간 후 농도가 0.2M 이 되도록 NaCl을 첨가하여 4시간 혼합하였다. 4시간 후 농도가 0.3M 이 되도록 NaCl을 첨가하여 12시간 혼합하였다. 12시간 후 WLBU2-R와 금 혼합물은 ~10,000 x g에서 20 분간 원심 분리하여 모은 뒤 상층액에 있는 반응하지 않은 앱타머를 제거하였고, 이 과정을 3회 반복하였다. 최종 금 나노입자- WLBU2-R 결합물은 0.1 M NaCl를 포함하는 10mM sodium phosphate buffer (pH 7.4)에 넣고 분산시켰다. 제조된 금 나노입자- WLBU2-R 결합물은 10% acrylamide 8M Urea gel에 전기 영동으로 분석하였고, 한 개의 금 나노입자에 45-50개의 WLBU2-R 이 결합됨을 확인하였다.(도 3)WLBU2-R pretreated and precipitated through the above 3-1 process was dissolved in water, added to the gold nanoparticles, and then combined with the salt aging method. Specifically, WLBU2-R was added to 7 nM gold nanoparticles (AuNP: WLBU2-R = 1:300) and thoroughly mixed, then NaCl was added to make the concentration 0.1M and mixed for 4 hours. After 4 hours, NaCl was added to the concentration to 0.2M and mixed for 4 hours. After 4 hours, NaCl was added to bring the concentration to 0.3M and mixed for 12 hours. After 12 hours, the WLBU2-R and gold mixture was collected by centrifugation at ~10,000 x g for 20 minutes, and unreacted aptamers in the supernatant were removed, and this process was repeated three times. The final gold nanoparticle-WLBU2-R complex was dispersed in 10mM sodium phosphate buffer (pH 7.4) containing 0.1 M NaCl. The prepared gold nanoparticle-WLBU2-R complex was analyzed by electrophoresis on a 10% acrylamide 8M Urea gel, and it was confirmed that 45-50 WLBU2-R were bound to one gold nanoparticle (Figure 3).
3-3. AuNP3-3. AuNPs WLBU2-RWLBU2-R -WLBU2 컨쥬게이트 제조-WLBU2 conjugate preparation
AuNPWLBU2-R 와 WLBU2 펩타이드 컨쥬게이트는 상기 3-2과 같이 제조되었다. 기능화된 금 나노 입자의 이차 구조의 형성을 방지하기 위해 AuNPWLBU2-R를 80℃에서 5분 간 pre-incubate 시켰다. 상온에서 5분간 보관 후, 펩타이드 (WLBU2) 와 PBS를 첨가 후, 기능화된 금나노에 펩타이드를 결합시키기 위하여 0.01M MgCl2를 넣어준다. 상온에서 10분 동안 반응시키고, 생성된 컨쥬게이트를 15,000 x g에서 10분 동안 원심분리 후 상층액을 제거하고 Tricine-SDS-PAGE GEL을 이용하여 전기 영동을 실시하여 결합을 확인하였 다. 그 결과, 한 개의 금 나노입자에 5-6개의 펩타이드가 결합하였음을 확인하였다 (도 4).AuNP WLBU2-R and WLBU2 peptide conjugate were prepared as in 3-2 above. To prevent the formation of secondary structures of functionalized gold nanoparticles, AuNP WLBU2-R was pre-incubated at 80°C for 5 minutes. After storing at room temperature for 5 minutes, add peptide (WLBU2) and PBS, and then add 0.01M MgCl2 to bind the peptide to the functionalized gold nano. The reaction was performed at room temperature for 10 minutes, and the resulting conjugate was centrifuged at 15,000 xg for 10 minutes, the supernatant was removed, and electrophoresis was performed using Tricine-SDS-PAGE GEL to confirm binding. As a result, it was confirmed that 5-6 peptides were bound to one gold nanoparticle (Figure 4).
실시예 4. 소동물 모델에서 AuNPExample 4. AuNPs in small animal models WLBU2-RWLBU2-R 에 의한 WLBU2 항균 펩타이드의 전달능 확인 Confirmation of delivery ability of WLBU2 antibacterial peptide by
세균에 감염된 동물에서, WLBU2 및 AuNPWLBU2-WLBU2를 각각 주입하여 항균 펩타이드 전달체의 전달능을 비교하는 실험을 진행하였다. 실험을 위하여 동물(마우스)은 30 내지 40%의 습도 및 22±1℃의 온도로 유지되는 동물 사육실에서 사육하였다. 실내의 조명은 12-h light/dark 주기로 하였다. 동물 프로토콜은 동물 실험에 대한 중앙대 Support Center에 의해 승인되었고, 동물은 프로토콜에 기재된 대로 처리되었다. In animals infected with bacteria, an experiment was conducted to compare the delivery ability of antibacterial peptide carriers by injecting WLBU2 and AuNP WLBU2- WLBU2, respectively. For the experiment, animals (mice) were raised in an animal breeding room maintained at a humidity of 30 to 40% and a temperature of 22 ± 1°C. Indoor lighting was set to a 12-h light/dark cycle. The animal protocol was approved by the Chung-Ang University Support Center for Animal Experiments, and animals were treated as described in the protocol.
6주령 BALB/c 마우스(Central Lab Animal Inc, Korea)에 P. aeruginosa PAO1 균주(1.5 x 106 )를 주입한 후, 1시간 및 2.5시간 이후에 Intravenous (I.V.)를 통하여 WLBU2(4mg/kg)및 AuNPWLBU2-R(10nM)-WLBU2(4mg/kg)를 각각 2회 반복하여 주입하고 마우스의 생존능을 관찰하였다. After injecting P. aeruginosa PAO1 strain ( 1.5 and AuNP WLBU2-R (10 nM)-WLBU2 (4 mg/kg) were each injected repeatedly twice and the survival of mice was observed.
그 결과, 항균 펩타이드(WLBU2)만을 주입한 경우와는 달리, 금 나노 입자와 앱타머가 결합된 전달체를 이용하여 항균 펩타이드를 전달한 경우(AuNPWLBU2-R(10nM)-WLBU2), 마우스의 생존능이 현저히 증가되는 것을 확인할 수 있었다. (도 5). 이는 항균 펩타이드의 전달력이 골드나노 전달체에 의해 향상되며, 결과적으로 항균력이 강화되는 효과를 나타냄을 보여주는 것이다. As a result, unlike when only antibacterial peptide (WLBU2) was injected, when antibacterial peptide was delivered using a delivery vehicle combining gold nanoparticles and aptamers (AuNP WLBU2-R (10nM)-WLBU2), the mouse's survival ability was significantly improved. An increase could be observed. (Figure 5). This shows that the delivery power of antibacterial peptides is improved by the gold nano-delivery carrier, resulting in enhanced antibacterial power.
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.So far, the present invention has been examined focusing on its preferred embodiments. A person skilled in the art to which the present invention pertains will understand that the present invention may be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative rather than a restrictive perspective. The scope of the present invention is indicated in the claims, not the foregoing description, and all differences within the equivalent scope should be construed as being included in the present invention.
Claims (7)
상기 금 나노 입자의 표면에 결합되는 앱타머(aptamer)를 포함하는, 항균 펩타이드 전달체이며,
상기 앱타머는 서열번호 1 내지 4의 염기 서열 또는 상기 서열번호 1 내지 4의 서열과 80% 이상의 서열 동일성을 가지는 염기 서열을 포함하는 앱타머로서, 항균 펩타이드 WLBU2에 특이적으로 결합하는 것임을 특징으로 하는 항균 펩타이드 전달체. gold nanoparticles; and
It is an antibacterial peptide carrier containing an aptamer bound to the surface of the gold nanoparticle,
The aptamer is an aptamer comprising the nucleotide sequence of SEQ ID NO: 1 to 4 or a nucleotide sequence having more than 80% sequence identity with the sequence of SEQ ID NO: 1 to 4, and is characterized in that it specifically binds to the antibacterial peptide WLBU2. Antibacterial peptide carrier.
상기 금 나노 입자는 10 내지 20nm의 직경을 가지는 것을 특징으로 하는, 항균 펩타이드 전달체. According to paragraph 1,
An antibacterial peptide delivery vehicle, wherein the gold nanoparticles have a diameter of 10 to 20 nm.
상기 항균 펩타이드는 슈도모나스 애루지노사(Pseudomonas aerusinosa), 아시네토박터 바우마니(Acinetobacter baumanii), 스트렙토코커스 고르도니(Streptococcus gordonii), 후소박테리움 뉴클레아툼(Fusobacterium nucleatum), 포르피로모나스 긴기발리스(Porphyromonas gingivalis), 프랜시셀라 툴라렌시스(Francisella tularensis), 여시니아 페스티스(Yersinia pestis), 버크홀데리아 슈도말레이 (Burkholderia pseudomallei), 스트렙토코커스 아우레우스(Staphylococcus aureus), MRSA, 엔테로코커스 패시움(Enterococcus faecium), 클렙시엘라 뉴모니아 (Klebsiella pneumoniae), 엔테로박터 클로아카(Enterobacter cloacae), 에스케리아 콜라이(Escherichia coli) 및 칸디다 종(Candida species)를 포함하는 군으로부터 선택되는 하나 이상의 균에 대한 항균 활성을 가지는 것임을 특징으로 하는 항균 펩타이드 전달체. According to paragraph 1,
The antibacterial peptide is Pseudomonas aerusinosa, Acinetobacter baumanii, Streptococcus gordonii, Fusobacterium nucleatum, Porphyromonas gingivalis (Porphyromonas gingivalis), Francisella tularensis, Yersinia pestis, Burkholderia pseudomallei, Streptococcus aureus, MRSA, Enterococcus faecium (Enterococcus faecium), Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, and one or more bacteria selected from the group comprising Candida species. An antibacterial peptide carrier characterized in that it has antibacterial activity against.
상기 앱타머를 금 나노 입자에 결합시키는 단계를 포함하는 항균 펩타이드 전달체의 제조 방법. Creating an aptamer that specifically binds to the antibacterial peptide WLBU2;
A method for producing an antibacterial peptide carrier comprising binding the aptamer to gold nanoparticles.
상기 항균 펩타이드 WLBU2에 특이적으로 결합하는 앱타머는 SELEX에 의해 제작된 서열번호 1 내지 4의 염기 서열 또는 상기 서열에 대하여 적어도 80% 이상의 서열 동일성을 가지는 염기 서열을 포함하는 앱타머인 것을 특징으로 하는 항균 펩타이드 전달체의 제조 방법.According to clause 4,
The aptamer that specifically binds to the antibacterial peptide WLBU2 is an aptamer comprising the nucleotide sequence of SEQ ID NO: 1 to 4 produced by SELEX or a nucleotide sequence having at least 80% sequence identity to the above sequence. Method for preparing antibacterial peptide carrier.
상기 금 나노 입자의 표면에 결합되는 항균 펩타이드 WLBU2에 특이적으로 결합하는 앱타머(aptamer)를 포함하는 항균 펩타이드 전달체를 포함하는 항균용 조성물. gold nanoparticles; and
An antibacterial composition comprising an antibacterial peptide carrier containing an aptamer that specifically binds to the antibacterial peptide WLBU2 bound to the surface of the gold nanoparticle.
상기 항균용 조성물은 의약품, 화장품, 의약외품, 동물용 의약품, 식품 첨가제 또는 사료 첨가제 중 어느 하나인 것을 특징으로 하는 조성물.According to clause 6,
The antibacterial composition is any one of pharmaceuticals, cosmetics, quasi-drugs, veterinary drugs, food additives, and feed additives.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2023/007375 WO2023234673A1 (en) | 2022-05-30 | 2023-05-30 | Antimicrobial protein carrier based on gold nanoparticle-aptamer conjugate and fabrication method therefor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220066226 | 2022-05-30 | ||
| KR20220066226 | 2022-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230167291A true KR20230167291A (en) | 2023-12-08 |
Family
ID=89166809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220184356A KR20230167291A (en) | 2022-05-30 | 2022-12-26 | Antimicrobial peptide delivery system and manufacturing method based on gold nanoparticles-aptamer conjugate |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20230167291A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102336120B1 (en) | 2019-06-05 | 2021-12-08 | 주식회사 엔이에스바이오테크놀러지 | Gold nanoparticle-aptamer conjugates-based antibody delivery system and preparation method thereof |
-
2022
- 2022-12-26 KR KR1020220184356A patent/KR20230167291A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102336120B1 (en) | 2019-06-05 | 2021-12-08 | 주식회사 엔이에스바이오테크놀러지 | Gold nanoparticle-aptamer conjugates-based antibody delivery system and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gupta et al. | Combatting antibiotic-resistant bacteria using nanomaterials | |
| Lokugamage et al. | Constrained nanoparticles deliver siRNA and sgRNA to T cells in vivo without targeting ligands | |
| Fröhlich et al. | Structure–activity relationships of siRNA carriers based on sequence-defined oligo (ethane amino) amides | |
| AU2011271830B2 (en) | Microvesicles derived from cell protoplast, and use thereof | |
| Vaks et al. | In vivo characteristics of targeted drug-carrying filamentous bacteriophage nanomedicines | |
| JP2022542389A (en) | Nanomaterials containing bound lipids and uses thereof | |
| Agostinelli et al. | Nanoparticle strategies for cancer therapeutics: Nucleic acids, polyamines, bovine serum amine oxidase and iron oxide nanoparticles | |
| CN111808886B (en) | In vitro or ex vivo methods for promoting the entry of an introduced agent into a cell | |
| KR100882611B1 (en) | Low molecular water soluble chitosan nanoparticles for delivery of gene carrier modified with folate as a target ligand and preparation method thereof | |
| Dai et al. | Bacterial magnetosomes as an efficient gene delivery platform for cancer theranostics | |
| US20210046172A1 (en) | Bacterial extracellular vesicles having reduced toxicity and use thereof | |
| AU669128B2 (en) | Synthetic transfection vectors | |
| Crooke et al. | Lung tissue delivery of virus-like particles mediated by macrolide antibiotics | |
| JP2006501156A (en) | Materials and methods related to polyion and substance delivery | |
| Xu et al. | Recruiting T‐Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co‐Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage‐Membrane‐Camouflaged Nanovesicles | |
| CN108611348B (en) | Preparation method and application of dendritic DNA assembly | |
| KR20230167291A (en) | Antimicrobial peptide delivery system and manufacturing method based on gold nanoparticles-aptamer conjugate | |
| Hassan et al. | Applications and hazards associated with carbon nanotubes in biomedical sciences | |
| WO2023165467A1 (en) | Ferritin nanocage vector loaded with small nucleic acid drug in inner cavity and use | |
| KR102494402B1 (en) | Nanoparticle-oligoT conjugates based messenger RNA delivery system | |
| Zuo et al. | Recent advances in nanomaterials for asthma treatment | |
| WO2023234673A1 (en) | Antimicrobial protein carrier based on gold nanoparticle-aptamer conjugate and fabrication method therefor | |
| CN114072505A (en) | Nucleic acid MAZZOCCHIO and methods of making and using same | |
| WO2023086816A1 (en) | Mineral-coated substrates for stabilization of rna-based therapeutic compositions | |
| CN110897998A (en) | Genetic engineering polypeptide nano hydrogel simultaneously loaded with hydrophobic drug and hydrophilic drug and preparation method thereof |